Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Application

17 Feb 2011 17:47

RNS Number : 4535B
GW Pharmaceuticals PLC
17 February 2011
 



 

GW Pharmaceuticals PLC ("GW Pharmaceuticals")

 

BLOCKLISTING APPLICATION

 

Porton Down, UK, 17 February 2011: GW Pharmaceuticals (AIM: GWP) hereby provides notification that application has today been made to the London Stock Exchange for admission to trading on AIM of three blocks of new ordinary shares of 0.1p each.

These new ordinary shares will be issued from time to time pursuant to the exercise of employee share options under the GW Pharmaceuticals share options schemes, as follows:

200,000 new ordinary shares for issue by the GW Pharmaceuticals Approved Share Option Scheme 2001.

400,000 new ordinary shares for issue by the GW Pharmaceuticals Executive Share Option Scheme.

600,000 new ordinary shares for issue by GW Pharmaceuticals Long Term Incentive Plan.

On exercise the shares will be issued credited as fully paid and will rank pari passu with the existing ordinary shares in issue.

It is expected that such admission will become effective on 23 February 2011.

 

 

For further information, please contact:

 

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

 

Peel Hunt LLP (Nominated Adviser)

James Steel/Vijay Barathan +44 (0) 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISDKODQOBKDABD
Date   Source Headline
10th May 20134:24 pmRNSHolding(s) in Company
9th May 20133:40 pmRNSTotal Voting Rights
8th May 20138:00 amRNSClosing of Initial Public Offering on Nasdaq
7th May 20137:00 amRNSSativex Commercialization Approval in Italy
1st May 20135:47 pmRNSPricing of U.S. Initial Public Offering
22nd Apr 20137:00 amRNSUS Patent Allowance for SATIVEX Formulation Spray
18th Apr 20132:23 pmRNSAmendment to Registration Statement for NASDAQ
12th Apr 201310:31 amRNSResults of General Meeting
10th Apr 20137:00 amRNSSativex moved to Schedule 4 of UK Drugs Act
3rd Apr 20137:00 amRNSNew US Patent Allowance for Delivery of SATIVEX
22nd Mar 20132:35 pmRNSPosting of Shareholder Circular
19th Mar 20132:46 pmRNSAppoints Stephen Schultz VP of Investor Relations
19th Mar 20131:10 pmRNSUpdate on Sativex in Germany
19th Mar 20131:01 pmRNSFiling for listing on NASDAQ
19th Feb 20133:16 pmRNSDirectorate Change
19th Feb 20139:30 amRNSBlocklisting Interim Review
4th Dec 201210:04 amRNSDirector/PDMR Shareholding
30th Nov 20122:54 pmRNSDirector/PDMR Shareholding
30th Nov 20122:50 pmRNSDirector/PDMR Shareholding
28th Nov 20127:00 amRNSPreliminary Results
28th Nov 20127:00 amRNSPhIIa Study Identifies New Anti-Diabetic Treatment
22nd Nov 201211:31 amRNSNotice of Results
12th Nov 20127:00 amRNSGW to Present at Lazard Healthcare Conference
12th Oct 20127:00 amRNSPositive German Sativex Data Presented at ECTRIMS
1st Oct 20127:00 amRNSAppointment of Chief Operating Officer
13th Sep 20127:00 amRNSPublication of New Epilepsy Data
20th Aug 201212:14 pmRNSDirector/PDMR Shareholding
17th Aug 20124:04 pmRNSBlocklisting Interim Review
22nd Jun 20127:00 amRNSGerman GBA establishes positive benefit of Sativex
13th Jun 201210:19 amRNSDirector/PDMR Shareholding
6th Jun 20124:03 pmRNSDirector/PDMR Shareholding
23rd May 20123:56 pmRNSDirector/PDMR Shareholding
22nd May 20127:00 amRNSThird Cancer Pain Trial Commences
22nd May 20127:00 amRNSInterim Results
8th May 20127:00 amRNSSuccessful completion of MRP for Sativex
26th Apr 201211:00 amRNSNotice of Results
23rd Apr 20127:00 amRNSSativex phase IIb pain trial results publication
16th Apr 20127:00 amRNSAlmirall Milestone
5th Apr 20127:00 amRNSBoard Changes
2nd Apr 20122:31 pmRNSDirector/PDMR Shareholding
30th Mar 20121:57 pmRNSDirector/PDMR Shareholding
15th Mar 20127:00 amRNSGW and Almirall Strengthen Strategic Collaboration
8th Mar 20127:00 amRNSAppointment of Professor Vincenzo Di Marzo
17th Feb 20127:00 amRNSBlocklisting Interim Review
7th Feb 20127:00 amRNSSATIVEX® Regulatory Approval Received in Austria
25th Jan 20121:46 pmRNSResult of AGM
11th Jan 201211:43 amRNSHolding(s) in Company
11th Jan 201211:42 amRNSHolding(s) in Company
28th Dec 201110:39 amRNSDirector/PDMR Shareholding
22nd Dec 20117:00 amRNSSativex Approval in Sweden

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.